Evidence map›Paper›PMID 34630108›Full record

ArticleFrontiers in pharmacology2021

Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy.

Jing Yu, Huanhuan Zhao, Xin Qi, Liping Wei, Zihao Li, Chunpeng Li, Xiaoying Zhang, Hao Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Exploring the Cardioprotective Spectrum-Effect Relationship ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Plin5, a New Target in Diabetic Cardiomyopathy.Oxidative medicine and cellular longevity · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jing YuDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Huanhuan ZhaoDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Xin QiDepartment of Cardiology, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin, China.
Liping WeiDepartment of Cardiology, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin, China.
Zihao LiDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Chunpeng LiDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Xiaoying ZhangDepartment of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.
Hao WuDepartment of Cardiology, Tianjin Union Medical Center, Nankai University Affiliated Hospital, Tianjin, China.
Tianjin Medical University · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AngIIcardiac hypertrophydapagliflozinmicePlin5/PPARα signaling

Identifiers

PMID34630108
PMCPMC8495133
OpenAlexW3202313602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.